Savara to host investor call to discuss top line results from pivotal phase 3 impala-2 trial of molgramostim nebulizer solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap)

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, wednesday, june 26, 2024, at 8:00am et to discuss top line results from the pivotal, phase 3 impala-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf) in pat.
SVRA Ratings Summary
SVRA Quant Ranking